Krystal Biotech to Present at Upcoming Scientific Conferences Read more about Krystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 Read more about Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer Read more about Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa Read more about Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference Read more about Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference
Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 Read more about Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer Read more about Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer Read more about Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels Read more about Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa Read more about Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
